Literature DB >> 11719827

Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy.

M E Cooper1.   

Abstract

Diabetic nephropathy seems to occur as a result of an interaction of metabolic and haemodynamic factors. Glucose dependent pathways are activated within the diabetic kidney. These include increased oxidative stress, renal polyol formation and accumulation of advanced glycated end-products. Haemodynamic factors are also implicated in the pathogenesis of diabetic nephropathy and include increased systemic and intraglomerular pressure and activation of various vasoactive hormone pathways including the renin-angiotensin system and endothelin. These haemodynamic pathways, independently and with metabolic pathways, activate intracellular second messengers such as protein kinase C and MAP kinase, nuclear transcription factors such as NF-kappaB and various growth factors such as the prosclerotic cytokine, TGF-beta and the angiogenic, permeability enhancing growth factor, VEGF. These pathways ultimately lead to increased renal albumin permeability and extracellular matrix accumulation which results in increasing proteinuria, glomerulosclerosis and tubulointerstitial fibrosis. Therapeutic strategies involved in the management and prevention of diabetic nephropathy include currently available treatments such as intensified glycaemic control and antihypertensive agents, particularly those which interrupt the renin-angiotensin system. More novel strategies to influence vasoactive hormone action or to inhibit various metabolic pathways such as inhibitors of advanced glycation, specific protein kinase C isoforms and aldose reductase are at present under experimental and clinical investigation. It is predicted that multiple therapies will be required to reduce the progression of diabetic nephropathy.

Entities:  

Mesh:

Year:  2001        PMID: 11719827     DOI: 10.1007/s001250100000

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  89 in total

Review 1.  Pathogenesis of diabetic nephropathy.

Authors:  Claudia van Dijk; Tomas Berl
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway.

Authors:  Jin H Li; Wansheng Wang; Xiao R Huang; Matthew Oldfield; Ann M Schmidt; Mark E Cooper; Hui Y Lan
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

Review 3.  Oxidative stress in diabetic nephropathy.

Authors:  N Kashihara; Y Haruna; V K Kondeti; Y S Kanwar
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 4.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

Review 5.  Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.

Authors:  M Dalla Vestra; N Simioni; A Masiero
Journal:  Int Urol Nephrol       Date:  2008-10-29       Impact factor: 2.370

Review 6.  Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice.

Authors:  M Meier; J Menne; H Haller
Journal:  Diabetologia       Date:  2009-02-24       Impact factor: 10.122

Review 7.  Appropriate drug therapy for improving outcomes in diabetic nephropathy.

Authors:  Robert D Toto
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

8.  Role of upstream stimulatory factor 2 in diabetic nephropathy.

Authors:  Shuxia Wang
Journal:  Front Biol (Beijing)       Date:  2015-05-13

9.  Biochemical effects of irbesartan in experimental diabetic nephropathy.

Authors:  Richa Vaishya; J Singh; Harbans Lal
Journal:  Indian J Pharmacol       Date:  2009-12       Impact factor: 1.200

10.  Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes.

Authors:  Elena Tarabra; Sara Giunti; Federica Barutta; Gennaro Salvidio; Davina Burt; Giacomo Deferrari; Roberto Gambino; Daniela Vergola; Silvia Pinach; Paolo Cavallo Perin; Giovanni Camussi; Gabriella Gruden
Journal:  Diabetes       Date:  2009-07-08       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.